Press releases

CHEPLAPHARM acquires product package from Bristol-Myers Squibb – significant expansion of our portfolio

CHEPLAPHARM Arzneimittel GmbH continues its successful expansion strategy by purchasing three further global niche products.

Read more / pdf

CHEPLAPHARM acquires global rights to Questran® from Bristol-Myers Squibb

CHEPLAPHARM Arzneimittel GmbH continues with its diversification strategy.

Read more / pdf

CHEPLAPHARM acquires product rights for ATACAND® and ATACAND® Plus from AstraZeneca in Europe

CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose...

Read more / pdf

CHEPLAPHARM invests 6 million euros in the expansion of its German headquarters in Greifswald – funded by own sources only

From August 2018, CHEPLAPHARM expands its Ziegelhof headquarters in the Hanseatic city of Greifswald with a new building on an area of 5,300 square...

Read more / pdf

CHEPLAPHARM’s successful Capital Markets debut: 780 million euros new lending facilities agreed and thus future financing sources secured

CHPLAPHARM Arzneimittel GmbH has successfully completed the refinancing of existing loans and promissory notes.

Read more / pdf

CHEPLAPHARM steps into Therapeutic Area on a large-scale

By acquiring the worldwide rights (except US) for the product VISUDYNE® from the Swiss Novartis Pharma AG, CHEPLAPHARM is now active in the...

Read more / pdf

CHEPLAPHARM receives credit ratings: A premiere for a medium-sized company in Mecklenburg-Western Pomerania

In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.

Read more / pdf

CHEPLAPHARM further enhances its portfolio in the Cardiology area

CHEPLAPHARM Arzneimittel GmbH is pleased to announce that we have signed definitive agreements with Bristol-Myers Squibb to acquire product SOTALEX®.

Read more / pdf

CHEPLAPHARM continues its expansion course and complements its portfolio with four further products

Right at the beginning of the year, the fast-growing pharmaceutical company CHEPLAPHARM Arzneimittel GmbH secures the product rights for CYMEVENE®,...

Read more / pdf

CHEPLAPHARM engaged DKSH to market its regional business in several Asian countries

Zurich (CH) / Greifswald (DE), December 15, 2017 – In a formal ceremony at the DKSH headquarters in Zurich, DKSH and CHEPLAPHARM Arzneimittel GmbH...

Read more / pdf